McCamish Mark Anthony

DirectorAVADEL PHARMACEUTICALS PLC (AVDL) · full profile →Form 4 · filed Feb 12, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
2 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 12, 2026Disposed to issuer(D)67K$21.00$1.4M0
Feb 12, 2026Disposed to issuer(D)22K$21.00$462K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 12, 2026Disposed to issuer(D)60K0
Feb 12, 2026Disposed to issuer(D)42K0
Feb 12, 2026Disposed to issuer(D)50K0
Feb 12, 2026Disposed to issuer(D)42K0
Feb 12, 2026Disposed to issuer(D)42K0
Feb 12, 2026Disposed to issuer(D)11K0
Feb 12, 2026Disposed to issuer(D)33K0
Feb 12, 2026Disposed to issuer(D)11K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-014444) within minutes of acceptance. Every field above traces to the original document. Verify it directly: